These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 21426060)

  • 1. Nanocapsules of platinum anticancer drugs: development towards therapeutic use.
    Bryde S; de Kroon AI
    Future Med Chem; 2009 Nov; 1(8):1467-80. PubMed ID: 21426060
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High cytotoxicity of cisplatin nanocapsules in ovarian carcinoma cells depends on uptake by caveolae-mediated endocytosis.
    Hamelers IH; Staffhorst RW; Voortman J; de Kruijff B; Reedijk J; van Bergen en Henegouwen PM; de Kroon AI
    Clin Cancer Res; 2009 Feb; 15(4):1259-68. PubMed ID: 19228729
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antitumor activity and biodistribution of cisplatin nanocapsules in nude mice bearing human ovarian carcinoma xenografts.
    Staffhorst RW; van der Born K; Erkelens CA; Hamelers IH; Peters GJ; Boven E; de Kroon AI
    Anticancer Drugs; 2008 Aug; 19(7):721-7. PubMed ID: 18594214
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization and cellular uptake of platinum anticancer drugs encapsulated in apoferritin.
    Xing R; Wang X; Zhang C; Zhang Y; Wang Q; Yang Z; Guo Z
    J Inorg Biochem; 2009 Jul; 103(7):1039-44. PubMed ID: 19501911
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mini-review: discovery and development of platinum complexes designed to circumvent cisplatin resistance.
    Kelland LR; Sharp SY; O'Neill CF; Raynaud FI; Beale PJ; Judson IR
    J Inorg Biochem; 1999 Oct; 77(1-2):111-5. PubMed ID: 10626362
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ubiquitous induction of resistance to platinum drugs in human ovarian, cervical, germ-cell and lung carcinoma tumor cells overexpressing isoforms 1 and 2 of dihydrodiol dehydrogenase.
    Deng HB; Adikari M; Parekh HK; Simpkins H
    Cancer Chemother Pharmacol; 2004 Oct; 54(4):301-7. PubMed ID: 15138708
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nanocapsules: lipid-coated aggregates of cisplatin with high cytotoxicity.
    Burger KN; Staffhorst RW; de Vijlder HC; Velinova MJ; Bomans PH; Frederik PM; de Kruijff B
    Nat Med; 2002 Jan; 8(1):81-4. PubMed ID: 11786911
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antitumor activity of a new platinum(II) complex with low nephrotoxicity and genotoxicity.
    Marzano C; Bettio F; Baccichetti F; Trevisan A; Giovagnini L; Fregona D
    Chem Biol Interact; 2004 Jun; 148(1-2):37-48. PubMed ID: 15223355
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evolution of chemotherapy with platinum compounds.
    Walker EM; Walker SM
    Ann Clin Lab Sci; 1999; 29(4):263-74. PubMed ID: 10528825
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Polymeric drug delivery of platinum-based anticancer agents.
    Haxton KJ; Burt HM
    J Pharm Sci; 2009 Jul; 98(7):2299-316. PubMed ID: 19009590
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The resurgence of platinum-based cancer chemotherapy.
    Kelland L
    Nat Rev Cancer; 2007 Aug; 7(8):573-84. PubMed ID: 17625587
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Platinum agents in the treatment of osteosarcoma: efficacy of cisplatin vs. carboplatin in human osteosarcoma cell lines.
    Robson H; Meyer S; Shalet SM; Anderson E; Roberts S; Eden OB
    Med Pediatr Oncol; 2002 Dec; 39(6):573-80. PubMed ID: 12376980
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of cellular accumulation and cytotoxicity of cisplatin with that of tetraplatin and amminedibutyratodichloro(cyclohexylamine)platinum(IV) (JM221) in human ovarian carcinoma cell lines.
    Mistry P; Kelland LR; Loh SY; Abel G; Murrer BA; Harrap KR
    Cancer Res; 1992 Nov; 52(22):6188-93. PubMed ID: 1423261
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nanocapsules: a novel lipid formulation platform for platinum-based anti-cancer drugs.
    Hamelers IH; de Kroon AI
    J Liposome Res; 2007; 17(3-4):183-9. PubMed ID: 18027238
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Overcoming cisplatin resistance of ovarian cancer cells by targeted liposomes in vitro.
    Krieger ML; Eckstein N; Schneider V; Koch M; Royer HD; Jaehde U; Bendas G
    Int J Pharm; 2010 Apr; 389(1-2):10-7. PubMed ID: 20060458
    [TBL] [Abstract][Full Text] [Related]  

  • 16. cis-Amminedichloro(2-methylpyridine) platinum(II) (AMD473), a novel sterically hindered platinum complex: in vivo activity, toxicology, and pharmacokinetics in mice.
    Raynaud FI; Boxall FE; Goddard PM; Valenti M; Jones M; Murrer BA; Abrams M; Kelland LR
    Clin Cancer Res; 1997 Nov; 3(11):2063-74. PubMed ID: 9815598
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preclinical antitumor evaluation of bis-acetato-ammine-dichloro-cyclohexylamine platinum(IV): an orally active platinum drug.
    Kelland LR; Abel G; McKeage MJ; Jones M; Goddard PM; Valenti M; Murrer BA; Harrap KR
    Cancer Res; 1993 Jun; 53(11):2581-6. PubMed ID: 8388318
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Advances in platinum chemotherapeutics.
    Harper BW; Krause-Heuer AM; Grant MP; Manohar M; Garbutcheon-Singh KB; Aldrich-Wright JR
    Chemistry; 2010 Jun; 16(24):7064-77. PubMed ID: 20533453
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mechanisms of resistance of human tumours to anticancer drugs of the platinum family: a review.
    Ferguson PJ
    J Otolaryngol; 1995 Aug; 24(4):242-52. PubMed ID: 8551538
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of topotecan for extending the platinum-free interval in recurrent ovarian cancer: an in vitro model.
    Horowitz NS; Hua J; Gibb RK; Mutch DG; Herzog TJ
    Gynecol Oncol; 2004 Jul; 94(1):67-73. PubMed ID: 15262121
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.